Search the Newsreel

Earnings call transcript: Alpha Cognition posts strong Q2 2026 sales growth

Alpha Cognition (ACOG) reported strong Q2 2026 results, with ZUNVEYL sales growing significantly by 71% sequentially to $6.0 million, driven by increased adoption in long-term care facilities. The company narrowed its net loss and reduced full-year operating expense guidance, leading to a positive after-hours …

Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update

Alpha Cognition Inc. announced its second-quarter 2026 financial results, highlighting a significant 71% quarter-over-quarter increase in ZUNVEYL net product revenue to $6.0 million and a 37% rise in bottles dispensed. The company also reported expanding prescriber base and penetration in long-term care facilities, alongside …

Alpha Cognition (NASDAQ:ACOG) Announces Quarterly Earnings Results

Alpha Cognition Q2 Results: Revenue Up 71% QoQ To $6 Million

Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates

Alpha Cognition Inc. Q2 2026: Revenue $6.09M, EPS $(0.40) — 10-Q Summary

Alpha Cognition Inc. (ACOG) reported its Q2 2026 results, showing revenues of $6.09 million, a significant increase year-over-year due to product sales from the newly launched ZUNVEYL. Despite higher product sales, the company posted a net loss of $8.79 million, although this was an …

Alpha Cognition reports Q2 revenue growth, narrows loss By Investing.com

ALPHA COGNITION ($ACOG) Releases Q2 2026 Earnings, Stock Rises

ALPHA COGNITION ($ACOG) announced its Q2 2026 earnings, reporting -$0.40 per share, which met analyst estimates, and revenue of $6,090,000, exceeding expectations. Following the announcement, the stock price rose by 8.7%. The article also details recent insider trading activity, with significant purchases, and outlines …

Alpha Cognition (ACOG) doubles H1 2026 revenue as cash burn accelerates

Alpha Cognition Inc. (ACOG) reported significant revenue growth in Q2 2026 and H1 2026, driven by strong sales of its Alzheimer's drug ZUNVEYL, with Q2 revenue up 283% year-over-year and H1 revenue up 110%. Despite this, the company remains unprofitable with a net loss …

Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Alpha Cognition Inc. (ACOG) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results …

Alpha Cognition (ACOG) to Announce Quarterly Earnings on Thursday

Alpha Cognition (NASDAQ:ACOG) is scheduled to release its Q2 2026 earnings on Thursday, August 13th, after market close. Analysts anticipate a loss of $0.39 per share on $4.38 million in revenue. The company previously reported a smaller loss than expected and exceeded revenue estimates …

Alpha Cognition Inc. (ACOG) shares bought by Opaleye Management

Opaleye Management Inc., a ten percent owner of Alpha Cognition Inc. (ACOG), recently purchased 52,900 shares of common stock through indirect holdings. These transactions included 50,000 shares bought on August 3, 2026, at $8.00 per share, and 2,900 shares on July 31, 2026, at …

Press Release: Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update

Alpha Cognition announced it will report its second-quarter 2026 financial results. The company will also provide a business update, likely covering recent developments and future plans. This information will be shared through an upcoming press release.

Alpha Cognition Inc (ACOG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Alpha Cognition Inc (ACOG) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Alpha Cognition Inc (ACOG), noting its current valuation score of 6.36 and ranking within the Pharmaceuticals industry. It highlights the company's P/E ratio of -6.42 and states that relevant data for P/B, P/S, and P/CF ratios have …

Is Alpha Cognition (NASDAQ:ACOG) In A Good Position To Invest In Growth?

Alpha Cognition (NASDAQ: ACOG) has a cash runway of about 21 months with US$54m in cash and US$30m annual cash burn, and analysts expect it to break even in about 3 years. The company's cash burn increased significantly by 309%, but this was accompanied …

Alpha Cognition receives European patent for Alzheimer’s drug

Alpha Cognition Inc. has been granted a European patent for a crystalline solid form of benzgalantamine, the active ingredient in its Alzheimer's drug ZUNVEYL. This patent could provide protection until 2042 across various European markets. The company, a biopharmaceutical firm, is focused on developing …

Alpha Cognition Inc (ACOG) Institutional Confidence

Alpha Cognition Inc (ACOG) has an institutional shareholding score of 5.00, placing it 72nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion recently increased by 59.12% quarter-over-quarter, reaching 52.64%. The largest institutional shareholder is Bill Nygren | OAKMX, holding 0.28% of …

Alpha Cognition Inc. (ACOG) holder Opaleye buys 130 shares

Opaleye Management Inc., a major holder of Alpha Cognition Inc. (ACOG), indirectly purchased 130 shares of common stock at $7.90 per share on July 24, 2026, through Opaleye, L.P. This transaction increased the fund's holdings to 2,995,323 shares, with an additional 100,000 shares held …

Alpha Cognition Inc. (ACOG) Surges 8.6%: Is This an Indication of Further Gains?

Alpha Cognition Inc. (ACOG) shares ended the last trading session 8.6% higher at $8.58. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 21.5% gain over the past four weeks. …

Alpha Cognition Inc (ACOG) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Alpha Cognition Inc (ACOG), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 4.89 and is trading between a resistance level …

Alpha Cognition Inc (ACOG) - Tradingkey Stock Score & Comprehensive Stock Analysis

Alpha Cognition Inc (ACOG) demonstrates healthy fundamentals and high growth potential, with its valuation considered fairly priced within the Pharmaceuticals industry. The stock has high institutional ownership and multiple analysts rate it as a "Buy" with an upside potential to $16.00. While the company …

Alpha Cognition Inc (ACOG) Cash Flow

This article provides a detailed overview of Alpha Cognition Inc's (ACOG) cash flow statements, including operating, investing, and financing activities. It presents quarterly and annual financial figures, along with year-over-year percentage changes for various cash flow components. The report also includes an FAQ section …

Alpha Cognition Inc (ACOG) Balance Sheet

This article provides the quarterly and annual balance sheets for Alpha Cognition Inc (ACOG), allowing users to evaluate the company's financial health, analyze fundamentals, and calculate key financial ratios. It details assets, liabilities, and shareholders' equity over several periods, and includes an FAQ section …

Alpha Cognition Inc (ACOG) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a financial overview of Alpha Cognition Inc (ACOG), focusing on its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. Key financial data like market …

Alpha Cognition Inc (ACOG) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Alpha Cognition Inc (ACOG), listing its major shareholders and their respective proportions. It also provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in shares held and proportions.

ACOG|Alpha Cognition Inc|Price:7.900|Chg%:-0.330

Alpha Cognition Inc. (ACOG) closed at $7.90, down 4.01%, with a market cap of $172.02M. The company, focused on neurodegenerative disease treatments, is rated "Buy" by analysts with a target price of $16.00, representing a 94.41% upside. Its fundamentals are strong, and its valuation …

Alpha Cognition Inc. (ACOG) sees 200,086-share buy by 10% holder

Opaleye Management Inc., a ten percent owner of Alpha Cognition Inc. (ACOG), indirectly purchased a total of 200,086 common shares on July 22–23, 2026. These shares were acquired for Opaleye, L.P. and a separately managed account at weighted average prices of $7.8337 and $7.7953 …

ACOG Options Chain — NASDAQ:ACOG

This article from TradingView provides an overview of the options chain for Alpha Cognition Inc. (ACOG) on the NASDAQ stock market. It highlights features like contract overview, chain volatility, and data for both call and put options, helping users track market movements and assess …

Alpha Cognition Inc. (ACOG) reports Q1 loss, tops revenue estimates

Alpha Cognition Inc. (ACOG) reported a loss in its first fiscal quarter but exceeded revenue estimates. The company's financial performance showed a mixed outcome with higher-than-expected sales.

Alpha Cognition (ACOG) Proxy Filing Summary

Alpha Cognition (ACOG) has scheduled its Annual General Meeting for June 19, 2025, where shareholders will vote on financial statements, director elections, auditor appointments, and a new stock and incentive plan. The board comprises six directors, a majority of whom are independent, with established …